Nicox SA

NXOA

Company Profile

  • Business description

    Nicox SA is an international ophthalmology company developing solutions to help maintain vision and improve ocular health. Its lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Its first product, VYZULTA in glaucoma, licensed exclusively to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE in allergic conjunctivitis, licensed in multiple geographies.

  • Contact

    Rue Evariste Galois
    Emerald Square, Batiment C
    Sundesk Sophia Antipolis
    Biot06410
    FRA

    T: +33 497245300

    E: [email protected]

    https://www.nicox.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    14

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,826.7048.800.56%
CAC 407,878.46111.751.44%
DAX 4024,549.56342.651.42%
Dow JONES (US)44,458.30217.540.49%
FTSE 1008,867.0212.840.15%
HKSE24,056.54164.220.69%
NASDAQ20,611.34192.870.94%
Nikkei 22539,663.93157.35-0.40%
NZX 50 Index12,760.208.41-0.07%
S&P 5006,263.2637.740.61%
S&P/ASX 2008,589.2050.600.59%
SSE Composite Index3,516.6423.590.68%

Market Movers